Status:
UNKNOWN
Dose Modification Requirement for Trelagliptin in Egyptian Population
Lead Sponsor:
British University In Egypt
Collaborating Sponsors:
Nermeen Ashoush
Shereen Mowaka
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
25-39 years
Phase:
PHASE4
Brief Summary
The proposed study will consider the pharmacokinetic evaluation of Trelagliptin after administration to Egyptian volunteers and the results will be compared with the other reported ethnic populations....
Detailed Description
The proposed study will consider the pharmacokinetic evaluation of Trelagliptin after administration to Egyptian volunteers and the results will be compared with the other reported ethnic populations....
Eligibility Criteria
Inclusion
- The good health of the human subjects was confirmed by a complete medical history and physical examination.
Exclusion
- Patients suffering from any chronic disease other than diabetes will be excluded from the study.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04374864
Start Date
March 1 2020
End Date
July 1 2020
Last Update
May 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The British University in Egypt
Cairo, El Sherouk, Egypt, 11837